The Hong Kong stock exchange has stressed the importance of having sophisticated investors for pre-revenue biotech companies seeking an initial public offering (IPO) in the city, as it is fielding a strong pipeline of hopefuls looking to capitalise on investors’ enthusiasm in health-related stocks.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
